Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 6/20 | 0.51 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 6/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.37 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.36 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.36 |
| ▸ | HRH1 | P35367 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23242608 | 0.88 | HTR2A (0.52) | HTR2AHRH4MAOBTRPA1AMY1A | |
| SCHEMBL30950723 | 0.88 | HTR2A (0.52) | HTR2AHRH4MAOBTRPA1AMY1A | |
| SCHEMBL23242615 | 0.87 | HRH4 (0.53) | HTR2AHRH4MAOBHRH1 | |
| SCHEMBL23242604 | 0.82 | HRH4 (0.50) | HTR2AHRH4MAPTMAOBHRH1 | |
| SCHEMBL23242513 | 0.82 | HRH4 (0.50) | HTR2AHRH4MAPTMAOBHRH1 | |
| SCHEMBL11505586 | 0.78 | TRPA1 (0.41) | HTR2ATP53MAPTMAOBTRPA1 | |
| SCHEMBL1365008 | 0.73 | TRPA1 (0.50) | HTR2AHRH4TP53MAPTTRPA1 | |
| SCHEMBL23242532 | 0.73 | HRH4 (0.44) | HTR2AHRH4MAOBHRH1 | |
| SCHEMBL23242612 | 0.69 | HTR2A (0.50) | HTR2AHRH4HRH1 | |
| SCHEMBL29800783 | 0.69 | HTR2A (0.50) | HTR2AHRH4HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114929688-B | 3- (4- (11H-dibenzo [ b, e ] [1,4] azepin-6-yl) piperazin-1-yl) -and 3- (4- (dibenzo [ b, f ] [1,4] oxazepin/thiazepin/diazepin-11-yl) piperazin-1-yl) -propionic acid derivatives as H1 and 5-HT 2A-receptor modulators for the treatment of sleep disorders | 阿莱瑞恩公司 | 2024-11-01 | — | — | CN | disclosed |
| CN-114929688-A | 3- (4- (11H-dibenzo [ b, e ] [1,4] azepin-6-yl) piperazin-1-yl) -and 3- (4- (dibenzo [ b, f ] [1,4] oxazepin/thiazepin/diazepin-11-yl) piperazin-1-yl) -propionic acid derivatives as H1 and 5-HT 2A-receptor modulators for the treatment of sleep disorders | 阿莱瑞恩公司 | 2022-08-19 | — | — | CN | disclosed |
| US-11046651-B2 | Piperazine substituted azapine derivatives and uses thereof | ALAIRION, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| US-20210114989-A1 | PIPERAZINE SUBSTITUTED AZAPINE DERIVATIVES AND USES THEREOF | Neumora Therapeutics, Inc. | 2021-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11046651-B2 | Piperazine substituted azapine derivatives and uses thereof | HTR2A, HTR5A, HTR2C | HTR2A 1/4885HRH4 31/4885TP53 4530/4885 |
| US-20210114989-A1 | PIPERAZINE SUBSTITUTED AZAPINE DERIVATIVES AND USES THEREOF | HTR2A, HTR5A, HTR2C | HTR2A 1/4885HRH4 31/4885TP53 4530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.